These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 6579564)

  • 1. Mechanism of resistance to anthracyclines and vinca alkaloids.
    Danø K; Skovsgaard T; Nissen NI; Friche E; Di Marco A
    Prog Clin Biol Res; 1983; 132C():231-46. PubMed ID: 6579564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics by calcium channel blockers and calmodulin inhibitors].
    Tsuruo T
    Gan To Kagaku Ryoho; 1984 Mar; 11(3 Pt 2):750-9. PubMed ID: 6585181
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-antitumor vinca alkaloids reverse multidrug resistance in P388 leukemia cells in vitro.
    Inaba M; Nagashima K
    Jpn J Cancer Res; 1986 Feb; 77(2):197-204. PubMed ID: 3082832
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reversal of acquired resistance to vinca alkaloids and anthracycline antibiotics.
    Tsuruo T
    Cancer Treat Rep; 1983 Oct; 67(10):889-94. PubMed ID: 6354436
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Studies on the mechanism of multidrug resistance].
    Inaba M
    Gan To Kagaku Ryoho; 1987 Mar; 14(3 Pt 2):807-14. PubMed ID: 3471182
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular pharmacology of anthracycline resistance and its circumvention.
    Tapiero H; Fourcade A; Munck JN; Zwingelstein G; Lampidis TJ
    Drugs Exp Clin Res; 1986; 12(1-3):265-73. PubMed ID: 3460753
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circumvention of resistance to anthracyclines by calcium antagonists and other membrane-perturbing agents.
    Kessel D
    Cancer Surv; 1986; 5(1):109-27. PubMed ID: 3297311
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anthracycline resistance in P388 murine leukemia and its circumvention by calcium antagonists.
    Kessel D; Wilberding C
    Cancer Res; 1985 Apr; 45(4):1687-91. PubMed ID: 3919944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-resistance patterns and antigen expression in Vinca alkaloid- and other multiple drug-resistant human leukemic cell lines.
    Beck WT; Danks MK; Cirtain MC; van Heiningen JN
    Prog Clin Biol Res; 1986; 223():3-10. PubMed ID: 3468517
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
    Jain N; Lam YM; Pym J; Campling BG
    Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [General observation on drug resistance of cancer cells].
    Inaba M
    Gan To Kagaku Ryoho; 1982 Feb; 9(2):165-76. PubMed ID: 6764100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Monoclonal antibodies to glycoproteins of Vinca alkaloid-resistant human leukemic cells.
    Danks MK; Metzger DW; Ashmun RA; Beck WT
    Cancer Res; 1985 Jul; 45(7):3220-4. PubMed ID: 3891080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26).
    Danks MK; Yalowich JC; Beck WT
    Cancer Res; 1987 Mar; 47(5):1297-301. PubMed ID: 3469013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
    Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
    Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modes of resistance to anthracyclines and other natural products.
    Kessel D; Romine M; Decker D
    Prog Clin Biol Res; 1986; 223():81-93. PubMed ID: 3543948
    [No Abstract]   [Full Text] [Related]  

  • 16. Chemosensitizers counteracting acquired resistance to anthracyclines and vinca alkaloids in vivo. A new treatment principle.
    Skovsgaard T; Danø K; Nissen NI
    Cancer Treat Rev; 1984 Mar; 11 Suppl A():63-72. PubMed ID: 6375864
    [No Abstract]   [Full Text] [Related]  

  • 17. Physical-chemical properties shared by compounds that modulate multidrug resistance in human leukemic cells.
    Zamora JM; Pearce HL; Beck WT
    Mol Pharmacol; 1988 Apr; 33(4):454-62. PubMed ID: 3162758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anthracycline resistance.
    Friche E; Skovsgaard T; Nissen NI
    Acta Oncol; 1989; 28(6):877-81. PubMed ID: 2692650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vivo resistance towards anthracyclines, etoposide, and cis-diamminedichloroplatinum(II).
    Seeber S; Osieka R; Schmidt CG; Achterrath W; Crooke ST
    Cancer Res; 1982 Nov; 42(11):4719-25. PubMed ID: 6889912
    [TBL] [Abstract][Full Text] [Related]  

  • 20. N-benzyladriamycin-14-valerate (AD 198)-resistant cells exhibit highly selective cross-resistance to other anthracyclines that circumvent multidrug resistance.
    Lothstein L; Hosey LM; Sweatman TW; Koseki Y; Dockter M; Priebe W
    Oncol Res; 1993; 5(6-7):229-34. PubMed ID: 7907237
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.